** Shares of therapy developer Dyne Therapeutics DYN.O fall 19.03% to $11.20
** Co revises timelines for data updates and submission for its genetic disorder therapy DYNE-101 after meeting with FDA
** DYNE-101 is being studied for the treatment of myotonic dystrophy type 1, a genetic disorder causing progressive muscle weakness and wasting
** Co revises main goal in the registration expansion cohort to change from baseline in middle finger myotonia, a symptom which causes delayed muscle relaxation, as measured by video hand opening test at 6 months, compared to placebo
** Data from the trial is now expected in mid-2026, compared to first half of 2026 expected previously
** Also pushes submission seeking accelerated approval to late 2026 from H1 2026
** Stock down ~47% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.